Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Surface Review and Letter: Preface

10.1016/S0218-625X(01)00124-5Surface Review and Letters85iii-SRLE

Use of paclitaxel coated drug eluting technology to improve central vein patency for haemodialysis access circuits: Any benefit?

10.5758/vsi.2020.36.1.21Vascular Specialist International36121-2

Effect of functional group (fluorine) of aromatic thiols on electron transfer at the molecule-metal interface

10.1021/ja056324aJournal of the American Chemical Society1283935-939JACS

One-step green hydrothermal synthesis of biocompatible graphene/TiO2 nanocomposites for non-enzymatic H2O2 detection and their cytotoxicity effects on human keratinocyte and lung fibroblast cells

Highly sensitive and selective immunosensors that can detect disease biomarkers at ultra-low levels in early stages are urgently needed to reduce mortality risks. A facile and efficient approach using sonochemical-assisted solvent graphene exfoliation and a hydrothermal synthesis method has been used to prepare graphene/titanium dioxide (G/TiO2) nanocomposites. Nanocomposites containing different ratios of graphene and TiO2 precursors were prepared to determine the optimum composition of G/TiO2 that has the highest conductivity and electrocatalytic properties. Characterisation methods such as X-ray diffraction (XRD), scanning electron microscopy (SEM), energy dispersive X-ray spectroscopy (EDX), transmission electron microscopy (TEM), and high resolution TEM (HRTEM) were used to study the crystallinity, surface characteristics, elemental composition, and morphology of the synthesised nanocomposites. The synthesised materials were also confirmed via Raman spectroscopy. Using ferricyanide as the redox active probe, cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS) analyses indicated that 1:8 ratio of G/TiO2 exhibited the best current response and the lowest charge transfer resistance (Rct) of 1525 Ω. The potential of G/TiO2 for electrochemical sensing application was investigated using hydrogen peroxide (H2O2), a by-product of most enzymatic processes, as the analyte of interest. The sensitivity of the sensor towards H2O2 was 0.557 μA mM-1, with a limit of detection (LOD) at 56.89 μM. An in vitro cell proliferation assay was carried out to investigate the biocompatibility of the nanocomposites. The half-maximal inhibitory concentration (IC50) values obtained were >500 μg ml-1 for human lung fibroblasts (MRC5) and 5-25 μg ml-1 for human skin cells (HaCat)

Intra-patient and inter-patient comparisons of DNA damage response biomarkers in Nasopharynx Cancer (NPC): Analysis of NCC0901 randomised controlled trial of induction chemotherapy in locally advanced NPC

10.1186/s12885-018-5005-2BMC Cancer181109

Bio-Mirror project for public bio-data distribution

10.1093/bioinformatics/bth219Bioinformatics20173238-3240BOIN

The medical, functional and social challenges faced by older adults with intellectual disability

Annals of the Academy of Medicine Singapore427338-349AAMS

Screening for cardiovascular disease risk factors at baseline and post intervention among adults with intellectual disabilities in an urbanised Asian society

10.1111/jir.12006Journal of Intellectual Disability Research583255-268JIDR

InfiniCortex - From proof-of-concept to production

10.14529/jsfi170207Supercomputing Frontiers and Innovations4287-10